Pros | Beats FD returns for both 3Y & 5Y duration. | Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | 5Y returns in the bottom 25% of the category. 3Y returns in the bottom 25% of the category. | 5Y returns in the bottom 25% of the category. |
INDMoney rank | - | 6/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 86 Cr | 8459 Cr | ||
Min Investment | SIP ₹200 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.22% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 30 | 40 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.47%) Apollo Hospitals Enterprise Ltd (5.73%) Torrent Pharmaceuticals Ltd (5.68%) Cipla Ltd (5.56%) Neuland Laboratories Ltd (4.85%) | Sun Pharmaceuticals Industries Ltd (13.55%) Lupin Ltd (7.59%) Divi's Laboratories Ltd (6.9%) Cipla Ltd (6.33%) Dr Reddy's Laboratories Ltd (5.83%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (92.22%) Basic Materials (7.78%) | Health (100%) | ||
Equity % | 98.46% | 99.45% | ||
Debt % | - | - | ||
P/E | 44.17 | 35.82 | ||
P/B | 5.76 | 5.53 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -2.11% | -0.39% | ||
3-Month Return | -1.18% | -0.98% | ||
6-Month Return | 2.39% | 0.07% | ||
1-Year Return | -1.44% | 1.19% | ||
3-Year Return | 21.26% | 22.55% | ||
5-Year Return | 13.79% | 16.99% |
Sharpe | 0.9 | 0.98 | ||
Alpha | -1.28 | -0.21 | ||
Beta | 0.92 | 0.91 | ||
Standard Deviation | 15.59 | 15.24 | ||
Information Ratio | -0.68 | -0.48 |
Description | LIC MF Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Karan Doshi | Sailesh Raj Bhan,Divya Sharma,Kinjal Desai,Lokesh Maru |